Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
PYC Therapeutics Limited ( (AU:PYC) ) has provided an update.
PYC Therapeutics Limited announced changes in its board of directors, with Peter Coleman being appointed as a new director and Alan Tribe concluding his directorship. These changes may impact the company’s strategic direction and governance, potentially influencing its operations and stakeholder interests.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics is a clinical-stage biotechnology company focused on developing RNA therapies for genetic diseases. Utilizing a proprietary drug delivery platform, PYC aims to enhance the potency of precision medicines within the RNA therapeutic class, targeting monogenic diseases with high clinical development success rates.
Average Trading Volume: 717,203
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$799.1M
Find detailed analytics on PYC stock on TipRanks’ Stock Analysis page.